Trials / Terminated
TerminatedNCT03958955
Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.
Efficacy and Safety of Twice-daily Application of Delgocitinib Cream 20 mg/g for 6 Weeks in Subjects With Active Discoid Lupus Erythematosus.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- LEO Pharma · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This was a double-blind, multi-centre, randomised, vehicle-controlled, within-subject phase 2a trial. The trial was designed to establish the efficacy and safety of delgocitinib cream in the treatment of adult subjects with discoid lupus erythematosus (DLE).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Delgocitinib cream | Cream for topical application. |
| DRUG | Delgocitinib cream vehicle | The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient. |
Timeline
- Start date
- 2019-07-09
- Primary completion
- 2020-04-15
- Completion
- 2020-04-30
- First posted
- 2019-05-22
- Last updated
- 2025-03-06
- Results posted
- 2021-06-28
Locations
19 sites across 4 countries: United States, Denmark, France, Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03958955. Inclusion in this directory is not an endorsement.